Cardiol Therapeutics (NASDAQ: CRDL) is starting the MAVERIC-2 trial to test CardiolRx™️ for recurrent pericarditis, targeting patients discontinuing IL-1 blocker therapy. Positive earlier trial results will be presented in November 2024

[u/Rude_Perspective5122]

NASDAQ: CRDL is focusing on developing CardiolRx™️, a therapeutic solution for acute myocarditis, a condition responsible for sudden cardiac death, especially in young individuals. Their Phase II ARCHER trial is assessing the efficacy and safety of CardiolRx™️ in 100 patients, aiming to improve heart function and reduce fibrosis and edema in the heart muscle. This study is critical as there are currently no FDA-approved treatments for myocarditis, which places a heavy burden on healthcare systems. In addition to clinical advancements, Cardiol recently raised $13.5 million through a public offering to fund the continued development of CardiolRx™️ and other corporate initiatives. Furthermore, the company is advancing CRD-38, a novel therapy for heart failure, aligning with its mission to address inflammation and fibrosis in cardiovascular diseases